{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T17:07:04Z","timestamp":1788887224919,"version":"build-2803163510"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study was to investigate whether different liquid formulations of a selected candidate drug could be utilized to improve oral absorption and subsequent in vivo exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Polyethylene glycol 400 (PEG400) formulations with and without pH adjustment and hydroxypropyl-\u03b2-cyclodextrin (CD) formulations were prepared alongside amorphous and crystalline suspensions, the latter as micro- and nanocrystals. The suspensions of the compound were manufactured and evaluated for solubility, dissolution rate and in vivo exposure in rats, dogs, and humans, whereas the PEG400 and CD formulations were administered only to rats and\/or dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Amorphous microsuspensions of the active pharmaceutical ingredient (API) demonstrated the most promising in vivo results. CD formulation resulted in significantly lower drug exposure than expected. When amorphous suspensions were administered, an absorption difference was observed between male and female rats and a greater than dose linear increase in exposure was noted between two doses in humans.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrated that amorphous suspensions of a newly selected candidate drug resulted in superior oral absorption compared with more commonly used liquid formulations of the API in all investigated species. However, progressing with an amorphous form always carries inherent risks regarding chemical and physical stability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag084","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:23:53Z","timestamp":1784546633000},"source":"Crossref","is-referenced-by-count":0,"title":["Amorphous particles enhance oral exposure\u2014a case study of a poorly soluble compound in preclinical, toxicology and early clinical studies"],"prefix":"10.1093","volume":"78","author":[{"given":"Sara","family":"Lindblom","sequence":"first","affiliation":[{"name":"Early Product Development, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca , Gothenburg, S-413 83 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Strimfors","sequence":"additional","affiliation":[{"name":"Bioscience Metabolism, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg, S-413 83 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6260-8797","authenticated-orcid":false,"given":"Kalle","family":"Sigfridsson","sequence":"additional","affiliation":[{"name":"Advanced Drug Delivery, Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca , Gothenburg, S-413 83 M\u00f6lndal ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"2026090812135177900_ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2004.01.034","article-title":"Pharmaceutical evaluation of early development candidates, \u201cthe 100 mg-approach\u201d","volume":"275","author":"Balbach","year":"2004","journal-title":"Int J Pharm"},{"key":"2026090812135177900_ref2","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.addr.2007.05.008","article-title":"Solubility of sparingly-soluble ionizable drugs","volume":"59","author":"Avdeef","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2026090812135177900_ref3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt formation to improve drug solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2026090812135177900_ref4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejps.2013.08.040","article-title":"Compound selection for development\u2014is salt formation the ultimate answer? Experiences with an extended concept of the \u201c100 mg approach\u201d","volume":"57","author":"Korn","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"2026090812135177900_ref5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.addr.2007.05.009","article-title":"Estimating drug solubility in the gastrointestinal tract","volume":"59","author":"Dressman","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"2026090812135177900_ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics9040041","article-title":"Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models","volume":"9","author":"Lin","year":"2017","journal-title":"Pharmaceutics"},{"key":"2026090812135177900_ref7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejps.2019.04.013","article-title":"Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: an UNGAP review","volume":"134","author":"Vertzoni","year":"2019","journal-title":"Eur J Pharm Sci"},{"key":"2026090812135177900_ref8","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?","volume":"98","author":"Brouwers","year":"2009","journal-title":"J Pharm Sci"},{"key":"2026090812135177900_ref9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/mp100049m","article-title":"Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media","volume":"7","author":"Fagerberg","year":"2010","journal-title":"Mol Pharm"},{"key":"2026090812135177900_ref10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ijpharm.2013.05.013","article-title":"Drug precipitation inhibitors in supersaturable formulations","volume":"453","author":"Xu","year":"2013","journal-title":"Int J Pharm"},{"key":"2026090812135177900_ref11","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jps.2600580817","article-title":"Dissolution behavior of polymorphs of chloramphenicol palmitate and mefenamic acid","volume":"58","author":"Aguiar","year":"1969","journal-title":"J Pharm Sci"},{"key":"2026090812135177900_ref12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0378-5173(87)90088-3","article-title":"Bioavailability and inhibitory effect for stress ulcer of simetidine polymorphs in rats","volume":"35","author":"Kokubo","year":"1987","journal-title":"Int J Pharm"},{"key":"2026090812135177900_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/DDDT.S72572","article-title":"Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers","volume":"9","author":"Blandizzi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"2026090812135177900_ref14","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1021\/cg200492w","article-title":"Solubility advantage of amorphous drugs and pharmaceutical cocrystals","volume":"11","author":"Babu","year":"2011","journal-title":"Cryst Growth Des"},{"key":"2026090812135177900_ref15","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of Biopharmaceutical Classification System class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J Pharm Sci"},{"key":"2026090812135177900_ref16","doi-asserted-by":"publisher","DOI":"10.1002\/9783527801756.ch13","volume-title":"Early Drug Development: Bridging a Preclinical Candidate to the clinic","author":"Sigfridsson","year":"2018"},{"key":"2026090812135177900_ref17","doi-asserted-by":"publisher","first-page":"6665","DOI":"10.1021\/jm701032y","article-title":"Trends in active pharmaceutical ingredient salt selection based on analysis of the orange book database","volume":"50","author":"Paulekuhn","year":"2007","journal-title":"J Med Chem"},{"key":"2026090812135177900_ref18","doi-asserted-by":"publisher","first-page":"4687","DOI":"10.1021\/mp400516b","article-title":"Salt and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt","volume":"10","author":"Sanphui","year":"2013","journal-title":"Mol Pharm"},{"key":"2026090812135177900_ref19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.xphs.2017.10.032","article-title":"The selection of a pharmaceutical salt\u2014the effect of the acidity of the counterion on its solubility and potential biopharmaceutical performance","volume":"107","author":"He","year":"2018","journal-title":"J Pharm Sci"},{"key":"2026090812135177900_ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.05.049","article-title":"Developing early formulations: practice and perspective","volume":"341","author":"Li","year":"2007","journal-title":"Int J Pharm"},{"key":"2026090812135177900_ref21","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3109\/03639045.2013.771645","article-title":"Subcutaneous administration of nano- and microsuspensions of poorly soluble compounds to rats","volume":"40","author":"Sigfridsson","year":"2014","journal-title":"Drug Dev Ind Pharm"},{"key":"2026090812135177900_ref22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/03639045.2018.1529184","article-title":"A case study where pharmaceutical salts were used to address the issue of low in vivo exposure","volume":"45","author":"Sigfridsson","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"2026090812135177900_ref23","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1021\/la052367t","article-title":"Amorphous drug nanosuspensions. 2. Experimental determination of bulk monomer concentrations","volume":"22","author":"Lindfors","year":"2006","journal-title":"Langmuir"},{"key":"2026090812135177900_ref24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.ijpharm.2019.06.015","article-title":"Sustained release and improved bioavailability in mice after subcutaneous administration of griseofulvin as nano- and microcrystals","volume":"566","author":"Sigfridsson","year":"2019","journal-title":"Int J Pharm"},{"key":"2026090812135177900_ref25","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.1021\/la700811b","article-title":"Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth","volume":"23","author":"Lindfors","year":"2007","journal-title":"Langmuir"},{"key":"2026090812135177900_ref26","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1080\/03639045.2019.1628769","article-title":"Nano- and microcrystals of griseofulvin subcutaneously administered to rats resulted in improved bioavailability and sustained release","volume":"45","author":"Sigfridsson","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"2026090812135177900_ref27","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cts.12546","article-title":"Initial clinical experience with AZD5718, a novel once daily oral 5-lipoxygenase activating protein inhibitor","volume":"11","author":"Ericsson","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2026090812135177900_ref28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/jps.2600750313","article-title":"Comparison of gastrointestinal pH in dogs and humans: implications on the use of beagle dog as a model for oral absorption in humans","volume":"75","author":"Lui","year":"1986","journal-title":"J Pharm Sci"},{"key":"2026090812135177900_ref29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0939-6411(99)00070-3","article-title":"Gastric pH profiles of beagle dogs and their use as an alternative to human testing","volume":"49","author":"Akimoto","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"2026090812135177900_ref30","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1021\/cr960371r","article-title":"The stability of cyclodextrin complexes in solution","volume":"97","author":"Connors","year":"1997","journal-title":"Chem Rev"},{"key":"2026090812135177900_ref31","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/jphp.12427","article-title":"Pharmacokinetics of cyclodextrins and drugs after oral and parenteral administration of drug\/cyclodextrin complexes","volume":"68","author":"Loftsson","year":"2016","journal-title":"J Pharm Pharmacol"},{"key":"2026090812135177900_ref32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2017.11.018","article-title":"Cyclodextrins: structure, physicochemical properties and pharmaceutical applications","volume":"535","author":"Jansook","year":"2018","journal-title":"Int J Pharm"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/8\/rgag084\/70535605\/rgag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/8\/rgag084\/70535605\/rgag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:14:07Z","timestamp":1788884047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag084\/8754501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag084","relation":{},"ISSN":["2042-7158"],"issn-type":[{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8]]},"article-number":"rgag084"}}